Vivian Ho, Ph.D., is the James A. Baker III Institute Chair in Health Economics, a professor in the Department of Economics at Rice University and a professor in the Department of Medicine at Baylor College of Medicine. Ho’s research examines the effects of economic incentives and regulations on the quality and costs of health care. Her research is widely published in economics, medical and health services research journals. Ho’s research has been funded by the National Institutes of Health (NIH), the Agency for Healthcare Research and Quality, and the American Cancer Society.
Ho has served on the Board of Scientific Counselors for the National Center for Health Statistics, as well as on the NIH Health Services, Outcomes and Delivery study section. She is also a founding board member of the American Society for Health Economists. Ho received her A.B. in economics from Harvard University, a graduate diploma in economics from The Australian National University and a Ph.D. in economics from Stanford University.
John Mendelsohn, M.D., is the L.E. and Virginia Simmons Fellow in Health and Technology Policy at the Baker Institute. His work focuses on the identification and evaluation of new health technologies, therapeutics and best practices, as well as the promotion of policy recommendations to improve national and global health outcomes.
Until September 2011, Mendelsohn served as president of The University of Texas MD Anderson Cancer Center in Houston. Prior to joining the Baker Institute, he was on sabbatical at the Broad Institute of MIT and Harvard. He remains on the MD Anderson faculty as co-director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.
Before joining MD Anderson, Mendelsohn led the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He also held the Winthrop Rockefeller Chair in Medical Oncology and served as co-head of the Program in Molecular Pharmacology and Therapeutics. Additionally, he was professor and vice chairman of medicine at Cornell University Medical College. Previously, Mendelsohn was founding director of a National Cancer Institute-designated cancer center at the University of California, San Diego. His research helped pioneer the development of cancer therapies that target the aberrant genes, gene products and cell-signaling pathways that cause the disease.
Mendelsohn has received the Fulbright Lifetime Achievement Medal (2005); the Dan David Prize in Cancer Therapy (2006); and the Lila Gruber Memorial Cancer Research Award and the Lifetime Achievement Award from the 10th International Workshop on Molecular Targeted Therapy of Cancer (2009).
He holds a bachelor’s degree in biochemical sciences magna cum laude from Harvard College and a medical degree cum laude from Harvard Medical School.
Anaeze C. Offodile II
Sep 23 2020 | Domestic Health Policy
Rachel A. Meidl
Sep 22 2020 | Center for Energy Studies